Occam Crest Management LP Raises Holdings in Nuvectis Pharma, Inc. $NVCT

Occam Crest Management LP lifted its holdings in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 31.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 380,000 shares of the company’s stock after acquiring an additional 90,000 shares during the period. Nuvectis Pharma makes up approximately 2.0% of Occam Crest Management LP’s investment portfolio, making the stock its 20th largest holding. Occam Crest Management LP owned 1.43% of Nuvectis Pharma worth $2,869,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Nuvectis Pharma by 4.8% during the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock worth $4,206,000 after acquiring an additional 31,903 shares during the last quarter. Iridian Asset Management LLC CT lifted its holdings in shares of Nuvectis Pharma by 44.5% during the fourth quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock worth $4,427,000 after purchasing an additional 180,699 shares during the period. Baldwin Wealth Partners LLC MA lifted its holdings in shares of Nuvectis Pharma by 11.2% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock worth $2,942,000 after purchasing an additional 39,164 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Nuvectis Pharma by 11.8% during the fourth quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after purchasing an additional 38,291 shares during the period. Finally, State Street Corp lifted its holdings in shares of Nuvectis Pharma by 13.1% during the fourth quarter. State Street Corp now owns 154,666 shares of the company’s stock worth $1,168,000 after purchasing an additional 17,950 shares during the period. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Stock Up 4.1%

Shares of NASDAQ:NVCT opened at $11.15 on Tuesday. The business has a fifty day moving average of $9.61 and a two-hundred day moving average of $8.66. The stock has a market cap of $295.81 million, a P/E ratio of -8.51 and a beta of -0.07. Nuvectis Pharma, Inc. has a 52-week low of $5.55 and a 52-week high of $13.34.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. On average, equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NVCT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvectis Pharma in a report on Friday, June 5th. HC Wainwright upped their target price on Nuvectis Pharma from $10.00 to $13.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvectis Pharma presently has an average rating of “Hold” and a consensus target price of $13.00.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.